Cambridge Oncometrix Company
Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer. A condition that is likely to affect 1 in 8 men at some stage of their lives. Cambridge Oncometrix is developing a non-invasive test that will allow men to check the health of their prostate regularly. A simplified version of the test will be available for home use. A more advanced version will be used in medical institutions. This test will be capable of accurately detecting aggressive forms of prostate cancer at the early stages of its development.